A stock sale is expected to bring City Therapeutics about $200 million.
City Therapeutics, Inc. (CTY) priced its upsized IPO of 11,111,111 shares at $18.00 per share, expecting to raise about $200 million. Trading is set to begin on Nasdaq on October 16, 2026. The offering is managed by Goldman Sachs, Jefferies, Stifel, and Oppenheimer.
How this was made
The 30-second read
Why it matters
The IPO introduces a new tradable security, creating immediate liquidity and price discovery. Market participants will assess the valuation against pipeline risk.
Market read
The announcement is a primary disclosure of a sizable biotech IPO, offering a fresh trading opportunity and adding to sector activity.
What to watch
Potential regulatory or clinical trial outcomes for City’s pipeline could quickly shift sentiment after the IPO.
Background
City Therapeutics is a clinical‑stage RNAi therapeutics company with several pipeline candidates. The IPO pricing marks its transition to a public company.
Ticker impact
City Therapeutics announced the pricing of its upsized IPO of 11,111,111 shares, expected to raise about $200 million and begin trading on Nasdaq on Oct 16, 2026.
likely modest downside as the market absorbs the new float, unless demand exceeds supply
The IPO is the first public offering of City Therapeutics, a clinical‑stage biotech, and the size (~$200 M) is material enough to affect its opening price.
Market effects
Adds another biotech IPO to a sector that has seen heightened investor interest, potentially boosting biotech sentiment.
US biotech market sees fresh capital inflow; limited broader regional effect.
Limited to investors tracking US biotech IPO pipeline.
Counterpoint
If demand for biotech IPOs wanes, the new float could depress City Therapeutics' price more than expected.
Key entities
- companyCity Therapeutics, Inc.
Clinical‑stage biotech launching an IPO.
- underwriterGoldman Sachs & Co. LLC
Joint book‑running manager for the offering.
